News

Pulmonary exacerbations — the flares that cause a sudden worsening in respiratory symptoms — contribute to the higher mortality and lung transplant rates seen in people with cystic fibrosis-related diabetes (CFRD), an analysis of adults in a U.K. CF registry reported. “These findings have important implications for clinical teams.

A Phase 1b/2 clinical trial testing WRAIR-PAM-CF1, Adaptive Phage’s experimental cocktail of bacteriophages, or viruses that selectively target and kill bacteria, is now recruiting cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infections. The study (NCT05453578) seeks to enroll up to 72 adults with CF who test positive…

A novel gene-editing treatment platform corrected the mutation that causes cystic fibrosis (CF) in multiple tissues throughout the bodies of mice, according to results of a first-of-its-kind study. “This is the first study looking at treating multiple organs affected by CF with a single gene editing treatment administered intravenously,” Alexandra…

Trikafta (elexacaftor, tezacaftor, and ivacaftor) was found to successfully lessen the microbial load in the airways of people with cystic fibrosis (CF) after one year of therapy, according to a new study. Treatment with the approved triple therapy markedly reduced the abundance of Pseudomonas aeruginosa and Staphylococcus…

Anemia is common among lung transplant recipients, and people with cystic fibrosis (CF) are at more than four times greater risk of developing anemia post-transplant compared to those with other lung diseases. That’s according to the study “Post-Transplantation Anemia and Risk of Death Following Lung Transplantation,”…

Trikafta, a triple therapy combining elexacaftor, tezacaftor, and ivacaftor, cleared Aspergillus fungus in the lungs and prevented severe infections in children and adults with cystic fibrosis (CF), a pilot study found. “These preliminary results are very encouraging and support the hypothesis that initiation of [Trikafta] therapy rapidly improves…

A new study suggests that the use of anti-inflammatory medications to modulate immune signaling proteins in people with cystic fibrosis (CF) may potentially reduce bacteria and avoid antibiotic resistance. Researchers found that different bacteria in the airways of CF patients induced the release of varying signaling proteins, called cytokines,…

For the second consecutive year, Owl Cyber Defense, a provider of network cybersecurity solutions, will be a presenting sponsor in the 22nd annual Swing for Cystic Fibrosis (CF) Charity Golf Classic — a tournament held to help raise awareness and funds for CF. The event is set…

Vitamin C supplements can increase how long vitamin E stays active in the body in people with cystic fibrosis (CF), a small study suggests. “It would seem to be clinically prudent for CF clinicians and nutritionists to recognize the importance of dietary and supplemental vitamin C levels and their…

The average lifespan for someone with cystic fibrosis (CF) is markedly longer in France than in Canada or Australia, a new study reports. Programs that help facilitate access to lung transplants in France may in part explain the difference, according to researchers. “For multiple reasons, which will need to…